The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EMETPRO: A multicenter, international, retrospective analysis evaluating patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) with early progression (EP).
 
Fabio Turco
Travel, Accommodations, Expenses - Bayer
 
Martino Pedrani
No Relationships to Disclose
 
Giuseppe Salfi
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst); Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/Merck (Inst); Bristol Myers Squibb Foundation (Inst); Janssen-Cilag (Inst)
 
Peter Slootbeek
No Relationships to Disclose
 
Matthew Labriola
No Relationships to Disclose
 
Amanda Broderick
No Relationships to Disclose
 
Anna Patrikidou
No Relationships to Disclose
 
Hortense Patry
No Relationships to Disclose
 
Consuelo Buttigliero
No Relationships to Disclose
 
Hirotsugu Uemura
Honoraria - Bristol-Myers Squibb Japan; Janssen; Takeda pharm.
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; Eisai; Janssen; MSD; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Takanobu Utsumi
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Rafael Morales-Barrera
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck/Pfizer; MSD; Sanofi
Speakers' Bureau - Astellas Pharma; Merck/Pfizer; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Merck; MSD; Pfizer; Roche/Genentech; Sanofi
 
Daniela Guevara
No Relationships to Disclose
 
Orazio Caffo
No Relationships to Disclose
 
Andrea Zivi
No Relationships to Disclose
 
Pedro Barata
Honoraria - UroToday
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
Silke Gillessen
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); InnoMedica (Inst); Ipsen (Inst); Macrogenics (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); PeerVoice (Inst); Pfizer (Inst)
Speakers' Bureau - AdMeTech Foundation (Inst); ASCO GU (Inst); Avalere Health (Inst); EPG Health (Inst); ESMO; German-speaking European School of Oncology (DESO); Intellisphere (Inst); Meister ConCept GmbH (Inst); Schweizerische Gesellschaft für Medizinische Onkologie; Silvia Grasso Consulting (Inst); Swiss Group for Clinical Cancer Research (SAKK); Swiss Group for Clinical Cancer Research (SAKK) (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Gilead Sciences; Intellisphere
 
Ricardo Pereira Mestre
No Relationships to Disclose